Supernus Pharmaceuticals, Inc. ( SUPN ) NASDAQ Global Market

Cena: 44.83 ( 3.49% )

Aktualizacja 08-22 21:58
NASDAQ Global Market
Branża: Drug Manufacturers - Specialty & Generic
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Supernus Pharmaceuticals, Inc., firma biofarmaceutyczna, koncentruje się na rozwoju i komercjalizacji produktów w leczeniu chorób centralnego układu nerwowego (CNS) w Stanach Zjednoczonych. Jego produktami komercyjnymi są Trokendi XR, produkt topiramatu o wydłużonym wydaniu wskazany do leczenia padaczki, a także do profilaktyki bólu głowy migreny; oraz Oxtellar XR, rozszerzona uwalniana okskarbazepina do leczenia monoterapii napadów padaczkowych częściowych u dorosłych i dzieci w wieku od 6 do 17 lat. Produkty komercyjne firmy obejmują również Qelbree, selektywny inhibitor wychwytu zwrotnego noradrenaliny wskazany w leczeniu zaburzenia nadpobudliwości deficytu uwagi (ADHD) u dzieci w wieku od 6 do 17 lat; Apokyn za ostre przerywane leczenie hipomobilności lub epizodów poza nim u pacjentów z zaawansowaną chorobą Parkinsona (PD); Xadago do leczenia lewodopa/karbidopa u pacjentów z PD doświadczającymi epizodów; Myobloc, produkt toksyny typu B wskazany do leczenia dystonii szyjki macicy i sialorrhea u dorosłych; Gocovri do leczenia dyskinez u pacjentów z PD; oraz Osmolex ER w leczeniu choroby Parkinsona i indukowanej lekiem reakcją pozapiramidową u dorosłych pacjentów. Ponadto jego kandydaci na produkty obejmują Qelbree (SPN-812), który zakończył badania kliniczne fazy III stosowane w leczeniu ADHD; SPN-830, kandydat na produkt kombinacji leków/urządzeń w późnym stadium do zapobiegania epizodom OFF u pacjentów z PD; SPN-817, nowy kandydat produktu w badaniach klinicznych fazy I w leczeniu ciężkiej padaczki; SPN-820, kandydat produktu w badaniach klinicznych fazy II w leczeniu odpornej depresji; oraz SPN-443 i SPN-446, które znajdują się w przedklinicznym etapie leczenia CNS. Firma sprzedaje swoje produkty za pośrednictwem hurtowników farmaceutycznych, apteków specjalistycznych i dystrybutorów. Firma została zarejestrowana w 2005 roku i ma siedzibę w Rockville w stanie Maryland.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 652
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 95.7913
Ilość akcji: Brak danych
Debiut giełdowy: 2012-05-01
WWW: https://www.supernus.com
CEO: Mr. Jack A. Khattar M.B.A.
Adres: 9715 Key West Avenue
Siedziba: 20850 Rockville
ISIN: US8684591089
Wskaźniki finansowe
Kapitalizacja (USD) 2 513 757 073
Aktywa: 1 342 701 000
Cena: 44.83
Wskaźnik Altman Z-Score: 5.2
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 39.0
Ilość akcji w obrocie: 96%
Średni wolumen: 853 818
Ilość akcji 56 073 100
Wskaźniki finansowe
Przychody TTM 651 972 000
Zobowiązania: 335 551 000
Przedział 52 tyg.: 29.16 - 45.01
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 1.1
P/E branży: 22.5
Beta: 0.866
Raport okresowy: 2025-11-03
WWW: https://www.supernus.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Timothy C. Dec Senior Vice President & Chief Financial Officer 704 027 1959
Dr. Jonathan Rubin M.B.A., M.D. Senior Vice President of Research & Development and Chief Medical Officer 662 529 1961
Dr. Padmanabh P. Bhatt Ph.D. Chief Scientific Officer & Senior Vice President of Intellectual Property 628 411 1957
Mr. Frank Mottola Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs 526 479 1973
Mr. Jack A. Khattar M.B.A. Founder, President, Chief Executive Officer, Secretary & Director 1 842 893 1961
Dr. Bryan A. Roecklein Ph.D. Senior Vice President of Corporate Development 0 0
Dr. Todd Horich M.B.A., Ph.D. Senior Vice President of Marketing, Commercial Operations & Market Access 0 0
Mr. Jeff Bozick Senior Vice President of Supply Chain 0 0
Mr. Kevin T. Anderson Esq. Compliance Officer 0 1962
Mr. Taylor Raiford Senior Vice President of Sales 0 0
Lista ETF z ekspozycją na akcje Supernus Pharmaceuticals, Inc.
Symbol ETF Ilość akcji Wartość
IJR 3 204 129 112 464 929
VB 1 298 740 40 936 284
IWM 1 235 288 43 358 613
VBR 829 287 26 139 126
SPSM 487 268 16 393 191
AVUV 480 327 16 119 774
IWN 413 504 14 513 995
DFAT 333 360 11 700 936
VTWO 274 762 8 660 498
CALF 269 146 9 447 024
SCHA 263 495 8 751 048
IJS 246 937 8 667 474
IJT 239 067 8 391 241
PJP 190 536 6 394 388
VIOO 185 366 5 842 736
DFSV 183 443 6 438 849
VHT 173 342 5 463 739
DFAS 157 765 5 537 551
SLYV 153 878 5 231 078
IHE 144 623 5 076 252
SLYG 139 877 4 695 038
DFAC 136 551 4 792 940
FNDA 132 711 4 398 693
AVSC 116 723 3 917 223
USVM 113 659 3 989 430
XPH 94 824 3 202 242
IUS3.DE 78 961 2 424 524
IDP6.L 78 961 2 771 519
ISP6.L 78 961 2 097 707
ITOT 71 626 2 514 080
FESM 71 370 2 384 471
2B78.DE 66 307 2 035 997
DRDR.L 66 307 1 761 551
HEAL.L 66 307 2 327 386
PRFZ 63 392 2 127 435
VIOV 55 321 1 743 717
PSCH 53 681 1 801 534
FYX 48 828 1 595 210
FSMD 48 139 1 608 323
SFLO 45 168 1 585 396
EES 44 229 1 552 437
DFUV 38 228 1 341 802
IWO 37 441 1 314 176
GSSC 34 596 1 130 251
VIOG 34 009 1 071 963
VTWV 32 605 1 027 709
BTEK.L 31 867 846 586
BTEC.L 31 867 1 118 521
2B70.DE 31 867 978 482
BTEE.L 31 867 1 118 521
SCHB 31 846 1 064 726
JPSE 31 135 1 092 838
2B77.DE 29 925 918 855
AGED.L 29 925 1 050 360
AGES.L 29 925 794 997
PSC 29 641 1 040 399
RSSL 27 551 967 040
ONEQ 25 671 857 668
JMEE 24 462 858 616
FHLC 24 034 802 975
RWJ 21 746 729 795
AVUS 20 180 677 240
VFMF 19 971 629 485
IJR.AX 19 817 1 029 294
SIXL 19 361 0
BBSC 17 600 617 760
SMLF 14 707 516 219
DSMC 13 968 490 276
IWV 12 433 436 414
SMLV 11 875 402 930
ESGV 11 790 371 620
VFQY 10 897 343 473
DFAU 10 778 378 307
ROSC 10 169 341 271
SPTM 10 110 339 847
FYT 10 044 328 137
XSU.TO 9 291 430 650
QVMS 8 579 287 911
OMFS 7 622 255 794
DXUV 7 221 253 457
SMMV 6 829 229 181
DCOR 6 686 234 678
UWM 5 460 191 646
SXRG.DE 4 778 146 703
CUSS.L 4 778 167 699
CUS1.L 4 778 126 928
CSUSS.MI 4 778 146 703
URTY 4 519 158 616
XJR 4 425 148 503
CAFG 4 381 153 773
IBRN 4 072 142 932
VTHR 4 051 127 687
VTWG 4 041 127 372
TILT 4 004 140 540
MMSC 3 626 118 461
PILL 3 473 121 902
XUU.TO 2 455 113 797
ISCB 2 160 75 812
AFSM 2 096 68 476
BIB 2 061 72 341
IBBQ 2 006 67 321
XSMC.TO 1 978 91 662
FAB 1 920 62 726
XSMH.TO 1 829 84 786
CSA 1 231 37 964
AVSU 1 229 41 245
QQQS 1 180 39 600
SAA 1 032 36 223
FNDB 993 33 104
V3AL.L 846 26 665
V3AB.L 846 20 207
V3AA.L 846 26 665
VLU 682 23 019
XBAL.TO 432 20 033
ESIX 426 14 378
CSF 383 11 811
XUH.TO 362 12 164
CBUG.DE 236 7 251
EWSA.AS 236 8 289
HDG 65 2 281
MMTM 58 1 942
XTR.TO 15 492
SC0K.DE 0 157 632
USML.L 0 175 675
PZW.TO 0 9 958
SBIO.L 0 576 050
RTYS.L 0 179 904
SBIO.MI 0 504 735
Wiadomości dla Supernus Pharmaceuticals, Inc.
Tytuł Treść Źródło Aktualizacja Link
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highest implied volatility of all equity options today. zacks.com 2025-05-14 19:31:06 Czytaj oryginał (ang.)
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-09 11:30:00 Czytaj oryginał (ang.)
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-08 11:30:00 Czytaj oryginał (ang.)
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-07 11:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen David Amsellem - Piper Sandler Operator Good afternoon and welcome to Supernus Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-05-07 02:55:17 Czytaj oryginał (ang.)
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-05-07 00:00:43 Czytaj oryginał (ang.)
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to break-even earnings per share a year ago. zacks.com 2025-05-06 22:30:34 Czytaj oryginał (ang.)
Supernus Announces First Quarter 2025 Financial Results First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024. globenewswire.com 2025-05-06 20:08:00 Czytaj oryginał (ang.)
Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - SUPN NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-06 11:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-05 11:20:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SUPN NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-02 11:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-05-01 11:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SUPN NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-04-30 11:30:00 Czytaj oryginał (ang.)
SUPN ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Supernus Pharmaceuticals, Inc. Shareholders Who Lost Money NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-04-29 11:30:00 Czytaj oryginał (ang.)
What Makes Supernus (SUPN) a New Buy Stock Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-04-28 17:05:44 Czytaj oryginał (ang.)
Shareholder Rights Advocates at Levi & Korsinsky Investigate Supernus Pharmaceuticals, Inc. (SUPN) Regarding Possible Securities Fraud Violations NEW YORK, NY / ACCESS Newswire / April 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-04-25 11:30:00 Czytaj oryginał (ang.)
Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-04-24 11:25:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. globenewswire.com 2025-04-23 21:14:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN NEW YORK, NY / ACCESS Newswire / April 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-04-21 11:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN) NEW YORK, NY / ACCESS Newswire / April 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-04-18 11:25:00 Czytaj oryginał (ang.)
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, Mass. globenewswire.com 2025-02-27 10:30:00 Czytaj oryginał (ang.)
SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc. NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-02-27 09:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details. NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-02-26 09:45:00 Czytaj oryginał (ang.)
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-25 21:35:30 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript seekingalpha.com 2025-02-25 20:56:55 Czytaj oryginał (ang.)
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.02 per share a year ago. zacks.com 2025-02-25 20:50:45 Czytaj oryginał (ang.)
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for fourth quarter and full year 2024 and associated Company developments. globenewswire.com 2025-02-25 18:01:00 Czytaj oryginał (ang.)
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-02-24 18:00:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses BOSTON, MA / ACCESS Newswire / February 24, 2025 / Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses. accessnewswire.com 2025-02-24 17:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-02-24 09:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SUPN NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-02-21 09:30:00 Czytaj oryginał (ang.)
SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc. NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com 2025-02-19 16:00:00 Czytaj oryginał (ang.)
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses. globenewswire.com 2025-02-19 13:33:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial On Tuesday, Supernus Pharmaceuticals, Inc. SUPN revealed the topline data from the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD). benzinga.com 2025-02-19 12:29:24 Czytaj oryginał (ang.)
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD) did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score to Week 4 (SPN-820 [LS mean ± Standard Error]: -12.3 ± 0.96 vs. placebo: -11.9 ± 0.96; p = not significant). There was no treatment difference between SPN-820 and placebo in the change from baseline to Week 4 for the secondary endpoints. The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events. globenewswire.com 2025-02-18 18:25:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. globenewswire.com 2025-02-11 18:30:00 Czytaj oryginał (ang.)
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2025-02-06 15:06:20 Czytaj oryginał (ang.)
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. globenewswire.com 2025-02-04 11:00:00 Czytaj oryginał (ang.)
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). globenewswire.com 2024-12-16 18:30:00 Czytaj oryginał (ang.)
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City. globenewswire.com 2024-11-26 19:00:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdom. globenewswire.com 2024-11-13 18:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities. seekingalpha.com 2024-11-12 13:57:22 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com 2024-11-05 00:51:38 Czytaj oryginał (ang.)
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-11-04 23:00:23 Czytaj oryginał (ang.)
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to loss of $0.29 per share a year ago. zacks.com 2024-11-04 22:36:09 Czytaj oryginał (ang.)
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder (MDD). globenewswire.com 2024-10-31 18:10:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024. globenewswire.com 2024-10-21 20:25:00 Czytaj oryginał (ang.)
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md. globenewswire.com 2024-10-17 20:05:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder. globenewswire.com 2024-10-10 21:12:00 Czytaj oryginał (ang.)
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her. globenewswire.com 2024-09-24 11:30:00 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate virtually in a fireside chat at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26, 2024, at 8:40 a.m. ET. globenewswire.com 2024-09-19 20:30:00 Czytaj oryginał (ang.)
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable. seekingalpha.com 2024-09-12 03:25:00 Czytaj oryginał (ang.)
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected. benzinga.com 2024-09-11 18:38:19 Czytaj oryginał (ang.)
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts. globenewswire.com 2024-08-28 20:15:00 Czytaj oryginał (ang.)
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). globenewswire.com 2024-08-19 11:00:00 Czytaj oryginał (ang.)
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect? The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-08-09 14:55:31 Czytaj oryginał (ang.)
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Annabel Samimy - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-08-07 02:05:26 Czytaj oryginał (ang.)
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-08-07 01:02:14 Czytaj oryginał (ang.)